Nuo Therapeutics, Inc. AURX

AURX Company Overview

Nuo Therapeutics, Inc. (ticker: AURX) is a regenerative medicine and medical technology company historically focused on autologous cellular therapies and point-of-care biologics used in wound care and tissue regeneration. The company operated primarily within the healthcare and medical device sectors, with an emphasis on platelet-rich plasma and related blood-derived therapeutic technologies designed to support healing in chronic wounds and orthopedic applications. Public filings and historical market disclosures indicate that the company’s principal commercial platform centered on products derived from a patient’s own blood components for use by healthcare providers.

The company evolved from earlier regenerative medicine and biologics initiatives and was previously known as Cytomedix, Inc. before adopting the Nuo Therapeutics name. Its business strategy historically emphasized proprietary processing systems and clinical support for advanced wound care. Publicly available disclosures indicate that the company experienced periods of restructuring, financing activity, and operational realignment as it attempted to commercialize its technologies in competitive healthcare markets. Certain aspects of the company’s recent operating status and scale are difficult to verify consistently across public sources, and some data remains inconclusive based on available public disclosures.